The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Over a decade of insights into genomic profiling in metastatic colorectal cancer from a phase I setting.
 
Martina Eriksen
Consulting or Advisory Role - Pierre Fabre
Travel, Accommodations, Expenses - Pierre Fabre
 
Laila Belcaid
No Relationships to Disclose
 
Iben Spanggaard
Honoraria - AstraZeneca
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Bioinvent (Inst); BioNTech SE (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CDR-Life (Inst); Dragonfly Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Incyte (Inst); Loxo/Bayer (Inst); Loxo/Lilly (Inst); MonTa Biosciences (Inst); MSD (Inst); Novartis (Inst); Orion (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Repare Therapeutics (Inst); Roche (Inst); Symphogen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Incyte
 
Martin Hoejgaard
Stock and Other Ownership Interests - Bavarian Nordic
Travel, Accommodations, Expenses - Repare Therapeutics
(OPTIONAL) Uncompensated Relationships - Amgen (Inst); Eikon Therapeutics (Inst); Incyte (Inst); Kinnate Biopharma (Inst); Repare Therapeutics; SERVIER (Inst)
 
Camilla Qvortrup
Consulting or Advisory Role - Merck KGaA; Pierre Fabre
Research Funding - miratis (Inst); MSD Oncology (Inst); Pfizer (Inst); pierre fabre (Inst); Roche (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Merck KGaA (Inst); Pierre Fabre (Inst); Roche (Inst); SERVIER (Inst)
 
Morten Mau-Soerensen
Employment - Genmab (I)
Stock and Other Ownership Interests - Genmab (I)
Consulting or Advisory Role - Astellas Pharma; BMS Denmark; Daiichi Sankyo/Astra Zeneca; MSD; Takeda
Research Funding - Astellas Pharma (Inst); Dako/Agilent Technologies (Inst); MSD (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; MSD
 
Ulrik Lassen
Honoraria - Bayer; Novartis; Pfizer
Consulting or Advisory Role - Bayer; Pfizer
Research Funding - BMS (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Pfizer (Inst); Roche (Inst)
 
Lise Ahlborn
No Relationships to Disclose
 
Ane Yde Schmidt
No Relationships to Disclose
 
Christina Yde
No Relationships to Disclose
 
Kristoffer Rohrberg
Honoraria - MSD; MSD
Consulting or Advisory Role - Abbvie; Genmab
Research Funding - Alligator Bioscience (Inst); AstraZeneca (Inst); Bayer (Inst); Bioinvent (Inst); BioNTech SE (Inst); Bristol-Myers Squibb (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Lilly (Inst); Loxo (Inst); Merus (Inst); MonTa Biosciences (Inst); MSD (Inst); Navire (Inst); Novartis (Inst); Orion Clinical (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Repare Therapeutics (Inst); Roche/Genentech (Inst); Symphogen (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca (Inst)